However, best to our knowledge, none of these or any other biomarkers have been generalized so far in HNSC, KIRC, LIHC, LUAD, STAD, and UCEC patients of different clinicopathological features. In our study, we have shown the significant (p < 0.05) up-regulation of CTHRC1 expression in HNSC, KIRC, LIHC, LUAD, STAD, and UCEC patients of various clinicopathological features (different cancer stages, patients races, genders, and age groups) as compared to the normal controls. This evidence concerns the gene CTHRC1 and gastric adenocarcinoma.